Tegaserod: a new 5-HT₄ agonist in the treatment of irritable bowel syndrome

Bibliography

• ROME II: A multinational consensus document on functional gastrointestinal disorders. Gut (1999) 45\(Suppl. 11).
   Google Scholar
• WHITEHEAD WE, PALSSON 0, JONES KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology (2002) 122:1140–1156.
   Google Scholar
• DROSSMAN DA, LI Z, ANDRUZZI E et al.: US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Sa. (1993) 38:1569–1580.
   Google Scholar
• TALLEY NJ, VAN ZINSMEISTER AR, DYKE C, MELTON LJ 3RD: Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 101:927–934.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD WE: Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am. Med. (1999) 107(5A): 33S–40S.
   Google Scholar
• TALLEY NJ, ZINSMEISTER AR, MELTON LJ 3RD: Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am. Epidemiol (1995) 142(1):76–83.
   PubMed Web of Science ®Google Scholar
• HAHN BA, SAUNDERS WB, MAIER WC: Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig. Dis. (1997) 42(12):2585–2590.
   Google Scholar
• CAMILLERI M: Management of the irritable bowel syndrome. Gastroenterology (2001) 120:652–668.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ: Serotoninergic neuroenteric modulators. Lancet (2001) 358(9298):2061–2068.
   PubMed Web of Science ®Google Scholar
• GERSHON MD: Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharma-col Titer. (1999) 13\(Suppl. 2):15–30.
   Google Scholar
• KIM DY, CAMILLERI M: Serotonin: a mediator of the brain-gut connection. Am. Gastroenterol (2000) 95(10):2698–2709.
   PubMed Web of Science ®Google Scholar
• KAMM MA: Review article: the complexity of drug development for irritable bowel syndrome. Aliment. Pharmacol Titer. (2002) 16:343–351.
   PubMed Web of Science ®Google Scholar
• LACY BE, YU S: Tegaserod a new 5-HT4agonist. Clin. Gastroenterol (2002) 34(1):27–33.
   Google Scholar
• DE PONTI F, TONINI M: Irritable bowel syndrome. New agents targeting serotonin receptor subtypes. Drugs (2001) 61(3):317–332.
   Google Scholar
• PFANNKUCHE HJ, BUHL T, GAMSE R,HOYER D, MATTES H, BUCHHEIT KH: The properties of a new prokinetically active drug, SDZ HTF 919. Neurogastro- enterol Mon] (1995) 7:280. Abstract.
   Google Scholar
• BOCKAERT J, FAGNI L, DUMUIS A: 5-HT4 receptors: an update. Handbook Exp. Pharmacol (1997) 129:439–474.
   Google Scholar
• LEFEVRE H, CONTESSE V, DELARUE C, VAUDRY H, KUHN JM: Serotonin-ergic regulation of adrenocortical function. Hormone Metabolic Res. (1998) 30:398–403.
   PubMedGoogle Scholar
• CORSI M, PIETRA C, TOSON G, TRIST D, TUCCITTO G, ARTIBANI W: harmacological analysis of 5-hydroxy-tryptamine effects on electrically stimulated human isolated urinary bladder. Br. Pharmacol (1991) 104:719–725.
   PubMed Web of Science ®Google Scholar
• TONINI M, MESSORI E, FRANCESCHETTI GP et al: Character-ization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. &J. Pharmacol (1994) 113:1–2.
   Google Scholar
• GRIDER JR, FOXX-ORENSTEIN AE, JIN JG: 5-hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology (1998) 115:370–380.
   PubMed Web of Science ®Google Scholar
• SCHUTZE K, BRANDSTATTER G, DRAGOSICS B, JUDMAIER G, HENTSCHEL E: Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment. Pharmacol The]: (1997) 11:387–394.
   PubMed Web of Science ®Google Scholar
• VAN OUTRYVE M, MILO R, VAN TOUSSAINT J, EEGHEM P: Prokinetic treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. Clin. Gastroenterol (1991) 13:49–57.
   Google Scholar
• FARUP PG, HOVDENAK N, WETTERHUS S, LANGE 0J, HOVDE 0, TRONDSTAD R: The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand. Gastroenterol (1998) 33:128–131.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ, PHILLIPS SF, HADDAD A et al.: GR 38032F (ondansetron), a selective 5 HT3 receptor antagonist, slows colonic transit in healthy man. Dig. Dis. Sci. (1990) 35(4):477–480.
   PubMedGoogle Scholar
• GORE S, GILMORE IT, HAIGH CG, BROWNLESS SM, STOCKDALE H, MORRIS Al: Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment. Pharmacol Ther. (1990) 4(2):139–144.
   PubMedGoogle Scholar
• JIN JG, FOXX-ORENSTEIN AE, GRIDER JR: Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol Exp. The]: (1999) 288(1):93–97.
   PubMedGoogle Scholar
• STONER MC, ARCUNI JC, LEE J, KELLUM JM: A selective 5-HT4 receptor agonist induces cAMP-mediated Cl- efflux from rat colonocytes. Gastroenterology (1999) 116(4):A648. Abstract.
   Google Scholar
• PRINS NH, VAN HASELEN JFWR, LEFEBVRE RA, BRIEJER MR, AKKERMANS LMA, SCHUURKES JA: Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br. Pharmacol (1999) 127:1431–1437.
   PubMed Web of Science ®Google Scholar
• APPEL S, KUMLE A, MEIER R: Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin. Pharmacol Ther. (1997) 62:546–555.
   PubMedGoogle Scholar
• FIORAMONTI J, MILLION M, BUENO L: Investigation on a 5-HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology (1998) 114(4):A752. Abstract.
   Google Scholar
• HUGE A, ZITTEL TT, KREIS ME, BECKER HD, JEHLE EC: Effects of tegaserod (HTF 919) on gastrointestinal motility and transit in awake rats. Gastroenterology (2000) 118:A403. Abstract.
   Google Scholar
• ZITTEL TT, HUGE A, KREIS ME, BECKER HD, JEHLE EC: Tegaserod (HTF 919), a new 5-HT4 receptor partial agonist, increases post-operative gastric and small intestine motility in rats. Gastroenterology (1999) 116:A1108. Abstract.
   Google Scholar
• NGUYEN A, CAMILLERI M, KOST LJ et al.: SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J. Pharmacol Exp. Ther. (1997) 280(3):1270–1276.
   PubMedGoogle Scholar
• COELHO AM, ROVIRA P, FIORAMONTI J, BUENO L: Antinociceptive properties of HTF 919 (Tegaserod), a 5-HT4 receptor partial agonist, on colorectal distensions in rats. Gastroenterology (2000) 118:A835. Abstract.
   Google Scholar
• SCHIKOWSKI A, MATHIS C, THEWISSEN M, ROSS HG, PAK MA, ENCK P: Dose-dependent modulation of rectal afferent sensitivity by a 5-HT4 receptor agonist. Gastroenterology (1999): 116:A643. Abstract.
   Google Scholar
• DEGEN L, MATZINGER D, MERZ M et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol The]: (2001) 15:1745–1751.
   Google Scholar
• APPEL S, KUMLE A, HUBERT M, DUVAUCHELLE T: First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist. Clin. Pharmacol (1997) 37:229–237.
   Google Scholar
• VON DER OHE MR, KLINGENBURG S, GOEBELL H: In vivo modulation of left colonic motor function by a 5-HT4 mechanism in healthy humans. Gastroenterology (1998) 114:A856. Abstract.
   Google Scholar
• PRATHER CM, CAMILLERI M, ZINSMEISTER AR, MCKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000): 118:463–468.
   PubMed Web of Science ®Google Scholar
• COFFIN B, FARMACHIDI JP, BASTIEA, BOUHASSIRA D: Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Gastroenterology (2002) 122:A311.
   Google Scholar
• APPEL-DINGEMANSE S, LEMARECHAL MO, KUMLE A, HUBERT M, LEGANGNEUX E: Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br. I Clin. Pharmacol (1999) 47:483–491.
   PubMed Web of Science ®Google Scholar
• ZHOU H, KHALILIEH S, LAU H et al:Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). Clin. Pharmacol (1999) 39:911–919.
   Google Scholar
• APPEL-DINGEMANSE S, HIRSCHBERG Y, OSBORNE S, POMMIER F, MCLEOD J: Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Ear: Clin. Pharmacol (2001) 56:889–891.
   Google Scholar
• APPEL-DINGEMANSE S, HOROWITZ A, CAMPESTRINI J, OSBORNE S, MCLEOD J: The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young. Aliment. Pharmacol The]: (2001) 15:937–944.
   PubMed Web of Science ®Google Scholar
• ZHOU H, KHALILIEH S, CAMPESTRINI J, APPEL-DINGEMANSE S, LACHMAN L, MCLEOD J: Effect of gastric pH on plasma concentrations of tegaserod (HTF 919) and its major metabolite in healthy subjects. Gastroenterology (2000) 118:A1206. Abstract.
   Google Scholar
• VICKERS AEM, ZOLLINGER M, DANNECKER R, TINES R, HEITZF, FISCHER V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab. Dispos. (2001) 29(10):1269–1276.
   PubMedGoogle Scholar
• APPEL-DINGEMANSE S, HUBERT M, ALLADINA L, MCLEOD J: Pharmacokinetics and safety of SDZ HTF 919, a new promotile drug, in healthy subjects and patients with hepatic cirrhosis. Digestion (1998) 59(53):A5331. Abstract.
   Google Scholar
• ZHOU H, MCLEOD J, ALLADINA L et al.: Pharmacokinetics of SDZ HTF 919 not altered in subjects with severe renal insufficiency requiring haemodialysis. Clin. Pharmacol Ther. (1999) 65: 03. Abstract.
   Google Scholar
• DRICI MD, EBERT SN, WANG WX et al.: Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. j. Cardiovasc. Pharmacol (1999) 34:82–88.
   PubMedGoogle Scholar
• Zelmac.'" (tegaserod) tablets. NDA Number 21–200, Briefing Documentation for June 26, 2000 GI Advisory Committee Meeting.
   Google Scholar
• ZHOU H, KHALILEH S, SVENDSEN K et al.: Tegaserod (HTF 919) does not affect theophylline pharmacokinetics (PK) in healthy subjects. Jim. .1 Gastroenterol (1999) 94:A182. Abstract.
   Google Scholar
• KALBAG J, MIGOYA E, OSBORNE S, LASSETER K, PINTO M, MCLEOD J: Tegaserod does not significantly affect the pharmacokinetics of dextromethorphan in healthy subjects. Gastroenterology (2000) 118:A1179. Abstract.
   Google Scholar
• LEDFORD P, ON N, LIGUEROS-SAYLAN M, CAMPESTRINI J, OSBORNE S: Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Gastroenterology (2000) 118:A1184. Abstract.
   Google Scholar
• ZHOU H, HOROWITZ A, LEDFORD PC et al: The effect of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. Chit. Pharmacol (2001) 41(10):1131–1139.
   Google Scholar
• ZHOU H, WALTER YH, HUBERT M et al.: Tegaserod (HTF 919) does not decrease the effectiveness of an oral contraceptive when coadministered to healthy female subjects. Gastroenterology (2000) 118:A1207. Abstract.
   Google Scholar
• MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol Ther: (2001) 15:1655–1666.
   Google Scholar
• HAMLING J, BANG CJ, TARPILA S, STEWART W, RUEEGG PC: Titration regimen indicates partial 5-HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS). Digestion (1998) 59 (Suppl. 3):735. Abstract.
   Google Scholar
• LANGAKER KJ, MORRIS D, PRUITT R,OTTEN M, STEWART W, RUEEGG PC: The partial 5-HT4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). Digestion (1998) 59\(Suppl. 3):20. Abstract.
   Google Scholar
• LEFKOWITZ M, SHI Y, SCHMITT C, KRUMHOLZ S, TANGHE J: The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am. Gastroenterol (1999) 94 (9):2676. Abstract.
   Google Scholar
• RUEGG PC, SHI Y, KRUMHOLZ S, TANGHE J, SCHMITT C: Tegaserod, a partial 5-HT4 agonist, improves abdominal bloating and altered stool consistency in irritable bowel syndrome (IBS). Am. J. Gastroenterol (1999) 94 (9):2685. Abstract.
   Google Scholar
• RUEGG PC, NAULT B, PECHER E, LANGAKER KJ, PRUITT R, WALD A: Tegaserod is well tolerated over the short and long-term in patients with irritable bowel syndrome. Am. J. Gatmenterol (1999) 94(9):2685. Abstract.
   Google Scholar
• LEFKOWITZ M, LIGOZIO G, GLEBAS K, HEGGLAND JE: Tegaserod provides relief of symptoms in female patients with irritable bowel syndrome (IBS) suffering from abdominal pain and discomfort, bloating and constipation. Gastroenterology (2001) 120:A22. Abstract.
   Google Scholar
• SCHOENFELD P, CHEY WD, DROSSMAN D, KIM HM, THOMPSON WG: Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Gastroenterology (2002) 122:A465.
   Google Scholar
• VELDHUYZEN VAN ZANTEN SJO, TALLEY NJ, BYTZER P, KLEIN KB, WHORWELL PJ, ZINSMEISTER R: Design of treatment trials for functional gastrointestinal disorders. Gut (1999) 45 (Suppl. II) :1169–1177.
   Google Scholar
• SIMREN M, ABRAHAMSSON H, SVEDLUND J, BJORNSSON ES: Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand. Gastroenterol (2001) 36(5):545–552.
   PubMed Web of Science ®Google Scholar
• LEFKOWITZ MP, RUEGG PC, SHI Y, BALDAUF DC: Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod. Gastroenterology (2000) 118:A145. Abstract.
   Google Scholar
• CAMILLERI M: Review article: tegaserod.Aliment. Pharmacol Ther. (2001) 15:277–289.
   PubMed Web of Science ®Google Scholar
• WHORWELL PJ, KRUMHOLZ S, MUELLER LISSNER S, SCHMITT C, DUNGER-BALDHAUF C, RUEGG PC: Tegaserod has a favourable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS). Gastroenterology (2000) 118(4):A5529.
   Google Scholar
• MORGENROTH J, RUEGG PC, DUNGER-BALDAUF C, APPEL-DINGEMANSE S, BLIESATH H, LEFKOWITZ M: Tegaserod, a 5-hydroxytryptamine type-4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Gastroenterol (2002). In press.
   Google Scholar
• TACK J, VOS R, JANSSENS J, SALTER J,JAUFFRET S, VANDENPLASSCHE G: Influence of tegaserod on proximal gastric sensory and motor function in man. Gastroenterology (2002) 122:A453.
   Google Scholar